iNanoBio

Executive Summary

iNanoBio is a nano-biotechnology spin-off from Arizona State University, commercializing a proprietary FDEC FET nano sensor platform. The company is based in Cambridge, Massachusetts and focuses on applications in healthcare diagnostics, genome sequencing, and industrial/security sensing. Founded in 2018, iNanoBio leverages a novel field-effect transistor (FET) sensing technology that enables highly sensitive, real-time detection of biomolecules and chemicals without labeling. This platform has the potential to disrupt traditional diagnostic methods by offering faster, cheaper, and more portable solutions. While the company is still in early stages with no disclosed funding or valuation, its technology has broad applicability across genomics, point-of-care diagnostics, and environmental monitoring. iNanoBio's ability to secure strategic partnerships, advance prototype development, or initiate clinical validation will be critical for its near-term growth and proof of concept.

Upcoming Catalysts (preview)

• Q3 2026Prototype validation for genome sequencing platform30% success
• Q4 2026Strategic partnership or licensing deal with diagnostics company25% success
• H1 2027Series A funding round or grant award20% success